Leading pharmaceutical company Eli Lilly has unveiled compelling results from its Phase III trial of tirzepatide, an investigational therapy for type 2 diabetes and obesity. Participants achieved up to 20% body weight reduction over 72 weeks—far surpassing placebo outcomes.
Obesity is a serious chronic condition often undertreated compared to other diseases, yet it profoundly affects physical, psychological, and metabolic health. Risks include hypertension, cardiovascular disease, certain cancers, and depression.
While no single cure exists, multiple strategies are available. Eli Lilly has been at the forefront, developing tirzepatide to target type 2 diabetes and obesity.
Following promising early trials, the Phase III study enrolled over 2,500 overweight patients across the US, Argentina, Brazil, China, India, Japan, Mexico, Russia, and Taiwan—all with weight-related conditions excluding diabetes.
Tirzepatide mimics GLP-1 and GIP hormones, key regulators of metabolism and appetite.
Participants received weekly subcutaneous injections of placebo or one of three tirzepatide doses (5mg, 10mg, or 15mg) for 72 weeks, alongside reduced-calorie diets and exercise recommendations.
All groups lost weight, but tirzepatide groups saw dramatically superior results: 15% average loss at 5mg, 19.5% at 10mg, and 20.9% (about 20kg) at 15mg. Placebo averaged just 3.1%.
Side effects were mostly mild to moderate, such as nausea, vomiting, and diarrhea.
Though not yet peer-reviewed, these results are groundbreaking. Eli Lilly submitted tirzepatide for FDA approval for diabetes last year (decision expected Q2); obesity approval filing is imminent.
